Cabozantinib Archives

Tag: Cabozantinib

Cabozantinib is an oral drug which works by blocking the growth of new blood vessels that feed a tumour. In addition to blocking the formation of new blood cells in tumours, Cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other “anti-angiogenic” drugs. It is a type of drug called a growth blocker. Cabozantinib has been studied or is already in research studies as a possible treatment for various types of cancer, including prostate cancer, ovarian cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. During my research, I found that it has a connection to Medullary Thyroid Cancer (MTC) which is a type of Neuroendocrine Cancer, frequently associated with Multiple Endocrine Neoplasia (MEN). Cabozantinib, under the brand name of ‘Cometriq’ was approved by the FDA in 2012 for use in MTC. Read more below

20 Sep 2024

By Ronny Allan

0 Comments

CABOMETYX® (cabozantinib) for pNET and epNET

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Cabozantinib

16th April 2026 - NICE decision on funding Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474] In development Reference number:GID-TA11613 Expected publication date: 21 May 2026 Final draft guidance After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474] and submitted it to NICE. The FDG has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FDG…

02 Jul 2024

By Ronny Allan

1 Comment

Phase 3 CABINET Clinical Trial – Cabozantinib (Cabometyx) for Advanced Neuroendocrine Tumours

Clinical Trials and ResearchAdvanced neuroendocrine cancer, Afinitor, Cabometyx, Cabozantinib, CB-839, Chemotherapy, Cometriq, ENETS, Everolimus, Lung Cancer, Metastatic Neuroendocrine Cancer, mTOR inhibitor, Multi tyrosine kinase inhibitors (TKIs), Neuroendocrine cancer, Neuroendocrine tumour (NET), Pancreatic NET (PanNET), Paraganglioma, Pheochromocytoma, PI3K inhibitor, Poorly differentiated, Prostate Cancer, Proteasome inhibitors, Renal cell carcinoma (RCC), Sunitinib (Sutent), Tyrosine kinase inhibitor (TKI), Vascular endothelial growth factor (VEGF), Well differentiated

Please note this drug was approved and is now covered in a new blog - click here Clinical Trial history retained below for reference purposes BREAKING NEWS - 6th August 2024 Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors. Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors – The FDA assigned a Prescription Drug User Fee Act target action date of April 3, 2025 – – Application is based on results from…

22 Jan 2019

By Ronny Allan

3 Comments

Clinical Trials: Lenvatinib Efficacy in Advanced Neuroendocrine Tumours

Clinical Trials and ResearchAdvanced neuroendocrine cancer, Afinitor, Cabozantinib, Clinical trial, Everolimus, Fibroblast growth factor receptor (FGFR), Lenvatinib (Lenvima), Lenvima, Metastatic Neuroendocrine Cancer, Multikinase inhibitor, Neuroendocrine tumour (NET), Platelet-derived growth factor receptor (PDGFR), Sunitinib (Sutent), Vascular endothelial growth factor (VEGF)

Lenvatinib (LENVIMA) in Neuroendocrine Cancer — Updated January 2026 What is Lenvatinib? Lenvatinib is a targeted therapy known as a multikinase inhibitor. The brand name is LENVIMA. These drugs work by inhibiting multiple intracellular and cell‑surface kinases involved in tumour growth, angiogenesis, and metastatic progression. Targets include: VEGFR PDGFR FGFR c‑KIT Flt3 Because tumour progression typically involves multiple signalling pathways rather than a single driver, multikinase inhibition is a logical therapeutic strategy. How does it compare with other targeted therapies used in NETs? Sunitinib (Sutent) – a multikinase inhibitor targeting VEGF pathways; approved for pancreatic NETs. Everolimus (Afinitor) – an…

24 Oct 2017

By Ronny Allan

2 Comments

Round up of NANETS 2017 – Let’s talk about NETs #NANETS2017

Awareness, Living with Neuroendocrine Cancer, Patient Advocacy, Survivorship, TreatmentAnxiety, Appendiceal NET, Bronchial NET, Cabozantinib, Diarrhea, Fatigue, Ga68 PET/CT, Lu-177, Lutathera, Lymph nodes, NETTER-1, North American Neuroendocrine Tumor Society (NANETS), PRRT, Quality of LIfe (QoL), Somatostatin analogues, Somatostatin receptors (SSTR), SSTR-PET

NANETS (North American Neuroendocrine Tumor Society) is one of the biggest NET conferences, bringing together NET Specialists from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field of Neuroendocrine Neoplasms (Tumors and Carcinomas). This is fairly complex stuff but much of it will be familiar to many. I’ve filtered out several outputs from the conference which I think are both relevant and topical to patients. The list is below allowing you to easily peruse and read further via linkages if you need to read more. Remember, some of these are extracts so do not…